Symposium Schedule
Friday, Dec. 7, 2018
Mahogany Ballroom at the Radisson Hotel
University of Toledo Health Science Campus
Beginning at 7:30 a.m.
PLENARY SPEAKER
Jian-Ting Zhang, Ph.D.
Professor of Pharmacology & Toxicology
Indiana University, School of Medicine
Indianapolis, IN
Dr. Jian-Ting Zhang was instrumental in starting a drug discovery program at Indiana University School of Medicine. He will reflect on the process and different cycles of fund raising to support the program and then elaborate on the successful project on targeting surviving, which is a member of the Inhibitor of apoptosis (IAP) gene family, existing as a homodimer.
The presentation will include perspectives for possibly establishing such a program at UT/ProMedica.
Program Objectives:
To promote the growth of translational cancer research and collaborations by
- Providing overviews of the individual research programs of scientists based in multiple colleges at UT
- Describing general plans for future cancer initiatives
- Increasing awareness of resources available to support cancer research at UToledo and ProMedica
2018 Agenda
Learn more about the schedule for the symposium. *Schedule subject to change.
7:30-8:00 a.m. |
***CONTINENTAL BREAKFAST *** |
WELCOME AND OPENING REMARKS |
|
8:00 a.m. |
Welcome |
8:15 a.m. |
Opening Remarks (Overview of the Cancer Research Program) |
8:30 a.m. |
“Unveiling a New Collaborative Precision Cancer Clinical Trials Program,
|
SESSION I: CANCER GENETICS AND BIOMARKER DISCOVERYModerator: Cynthia Smas, D.Sc. |
|
9:00 a.m. |
Addressing the Proteogenomic Platform in Precision Therapeutics” |
9:15 a.m. |
Genomic sequencing platform using Foundation 1
|
SESSION II: CANCER THERAPEUTICS I
|
|
9:30 a.m. |
“Inhibiting Bromodomain Protein 9 (BRD9) in melanoma” |
9:45 a.m. |
“Targeting NAD and NADP-dependent call signaling for new anti-cancer therapy” |
10:00 a.m. |
“Novel technologies to overcome drug resistance in cancer” |
10:15–10:30 a.m. | BREAK |
SESSION III: STUDENT QUICK SHOT PRESENTATATIONSModerator: Kandace Williams, Ph.D. |
|
10:30 a.m. |
“SGEF forms a tenary complex with Scribble polarity complex members and regulates
E-cadherin based epithelial junction architecture and polarity” |
10:35 a.m. |
“RKIP-RhoA axis inhibits breast cancer invasion and metastasis by promoting adherens
junctions” |
10:40 a.m. |
"Surgical Tumor Samples to Patient Derived Cell Lines: Processing and Culture Techniques" |
10:45 a.m. | “Fine-Tuning Precision Diagnostics for Identification of Clinically Actionable Mutations” Daniel Craig, Pre-doctoral Student, Dept. of Medicine |
10:50 a.m. | “The role of Rho GTPase-activating protein ARHGAP17 in invadopodia dynamics” Gabriel Kreider-Letterman, Pre-doctoral Student, Dept. of Biological Sciences |
10:55 a.m. |
“The CXCR4-LASP1 axis in tumor progression and metastasis in triple-negative breast
cancer cells” |
SESSION IV: MECHANISMS OF INVASION & METASTASISModerator: Deborah Vestal, Ph.D. |
|
11:00 a.m. | “Mitochondrial fission regulator 2 (MTFR2) contributes to faithful chromosome segregation” Yibo Luo, Ph.D., Dept. of Biological Sciences |
11:15 a.m. | “Identification of novel regulators of invadopodia formation” Rafael Garcia Matta, Ph.D., Dept. of Biological Sciences |
11:30 a.m. | “Targeting the expression of tumor suppressor gene RKIP for cancer therapy”
Kam Yeung, Ph.D., Dept. of Cancer Biology |
11:45 a.m.–12:45 p.m. | LUNCH |
PLENARY LECTURER |
|
12:45 p.m. |
Introduction |
12:55-1:30 p.m. |
“Targeted Drug Discovery Program,
|
SESSION V: CANCER THERAPEUTICS II
|
|
1:30 p.m. |
“Targeting the cytoskeleton and formin machinery to halt tumor cell invasion” |
1:45 p.m. |
“Repurposing of FDA Approved Drugs for Precision BIRC5 Targeted Therapy for Pancreatic
Ductal Adenocarcinoma” |
2:00 p.m. |
“The CD3’s Compound Library and Its Direction Toward Anticancer Research” |
SESSION VI: RESOURCES TO SUPPORT CANCER RESEARCHModerator: Maurice Manning,, Ph.D. |
|
2:15 p.m. |
“Kinome array profiling of complex biological samples” |
2:30 p.m. |
“Repurposing drugs and the FDA approved drug library” |
2:45 p.m. |
“Shared Resources Available in the UToledo Integrated Core Facilities to Aid in Cancer
Research” |
SESSION VII: CANCER THERAPEUTICS III
|
|
3:00 p.m. |
“Restoration of nitric oxide synthase function as a novel immunotherapy for breast
cancer” |
3:15 p.m. |
“A Nuclear Complex of AR and TM4SF3 is a Novel Target for Prostate Cancer Therapy” |
3:30 p.m. |
“Role of chemokine receptors and their adaptor protein LASP1 in breast cancer” |
3:45 p.m. |
Concluding Remarks |
Continental breakfast and lunch will be provided.
Back to Top</p